Health Condition 1: K746- Other and unspecified cirrhosis ofliver
Conditions
Interventions
Intervention1: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
Institute of Liver and Biliary Sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1) Clinical / radiological /histologic diagnosis of cirrhosis (Child A&B) 2) Age >18 years 3) Advanced compensated liver disease of different etiology(Viral,metabolic,alcoholic) Upper GI bleed 4) Valid consent 5) No history of NSBB use in last 6 weeks
Exclusion criteria
Exclusion criteria: 1) Age > 70 years 2) Portal vein thrombosis 3) Underlaying shunts 4) Spleen anteroposterior diameter 5) Non cirrhotic portal hypertension 6) Only PHG, Ectopic varices 7) Heart rate 8) Pregnancy 9) obese(BMI >30mm of Hg) 10) HIV 11) HCC / Other malignancy 12) Other Comorbidities: Chronic kidney disease [ CrCl 9) 13) AST/ALT >5 times 14) Drug allergies 15) ACLF 16) Narrow intercoastal space 17) Failure to give informed consent from family members. 18) Patient enrolled in other clinical study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in HVPG and its correlation with non-invasive methods.Timepoint: 6 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| AAR, APRI, FIB 4 index, CSPH risk score,fibrosis index, GPR, King score, Lok score are other non invasive testsTimepoint: 6 weeks;Assessment of severity of portal hypertension by non-invasive methodsTimepoint: 6 weeks;Comparison of hypersplenism (Splenic volume and area) and hematological parameters before and after treatmentTimepoint: 6 weeks;Correlation and Cut-off values for non-invasive methods in responders and non-responders in relation to HVPGTimepoint: 6 weeks;Diagnosis and response assessment by convolutional neural network- AI based modelTimepoint: 6 weeks;Prognostic implication of HVPG rebleed on EVL with beta-blockersTimepoint: 6 weeks | — |
Countries
India
Contacts
Public ContactDr Shiv Kumar Sarin
Institute of Liver and Biliary Sciences
Outcome results
None listed